Heterocyclic Compounds

Matches 1 - 50 out of 9,425	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/083086A1	BICYCLIC DERIVATIVE INTEGRIN INHIBITOR A bicyclic αvβ1, αvβ6 and αvβ8 integrin inhibitor compound represented by formula (I), and a racemate, stereoisomer, tautomer, solvate, polymorph, metabolite, ester, prodrug or pharmaceutically acceptable salt thereof, and a pharma...
WO/2024/083256A1	PAN-KRAS DEGRADING AGENT, AND PREPARATION METHOD THEREFOR AND USE THEREOF Provided in the present invention are a pan-KRAS degrading agent, and a preparation method therefor and the use thereof. Specifically, disclosed in the present invention are a small molecule compound for targeted degradation of the pan-K...
WO/2024/083980A1	BICYCLIC FERROPORTIN INHIBITORS The invention relates to novel compounds of the general formula (I-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, ...
WO/2024/084217A1	3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein R1, B1, B2, B3, B4, B5, and...
WO/2024/086296A1	COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K The present disclosure relates to the field of medicinal chemistry. In particular, the disclosure relates to a new class of small-molecules having a quinazoline structure or a quinoline structure according to Formula (I), wherein Ring A,...
WO/2024/086570A1	POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 N-Biarylmethylene substituted pyrrolopyridinone, pyrrolopyrazinone, pyrrolopyrimidinone, and isoindolin-1-one compounds having a tertiary alcohol-containing group substituted on the biarylmethylene are positive allosteric modulators of t...
WO/2024/084390A1	COMPOUNDS FOR THE ACTIVATION OF AMPK Described herein are compounds of Formula I, wherein the variables are defined herein, their use as activators from AMPK, pharmaceutical compositions containing such compounds and their use to treat, for example, heart failure or periphe...
WO/2024/086837A1	METHODS OF SYNTHESIS FOR CUCURBITURIL COMPOUNDS Disclosure herein relates to, inter alia, inventive cucurbituril compounds and novel methods of preparing thereof using a glycoluril compound having the formula (II), a glycoluril compound having the formula (II'), a glycoluril bis-ether...
WO/2024/083258A1	KRAS G12C DEGRADATION AGENT, AND PREPARATION METHOD AND USE THEREFOR Disclosed in the present invention are a KRAS G12C degradation agent, and a preparation method and use therefor. The KRAS G12C degradation agent in the present invention is a compound as shown in formula I or I', and/or a stereoisomer, e...
WO/2024/083223A1	MACROCYCLIC COMPOUNDS AND MEDICAL USE THEREOF The present disclosure relates to macrocyclic compounds and the medical use thereof, the structures of the macrocyclic compounds being represented as formula (I). The present disclosure also relates to a method for preparing the compound...
WO/2024/083168A1	OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF Provided herein are oxazepinyl compounds comprising a 6-aza moiety that are useful in the treatment of cancers.
WO/2024/083246A1	KRAS INHIBITORS The present disclosure relates to compounds that inhibit KRAS. In particular, the present disclosure relates to compounds that inhibit the activity of KRAS G12D or KRAS G12V, pharmaceutical compositions comprising the compounds and metho...
WO/2024/078436A1	HETEROCYCLIC PYRIMIDINE COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF The present disclosure discloses a compound having formula (I) or a pharmaceutically acceptable salt thereof which acts as a USP1 inhibitor, a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt the...
WO/2024/080330A1	SULFONAMIDE COMPOUND AND HARMFUL-ARTHROPOD CONTROLLING COMPOSITION CONTAINING SAME The present invention provides a compound having an excellent control effect against harmful arthropods. A compound represented by formula (1) and an N oxide thereof have an excellent control effect against harmful arthropods. [In the fo...
WO/2024/040109A3	KRAS INHIBITORS The present disclosure provides KRAS inhibitors. Methods of treating cancers using the compounds are also provided.
WO/2024/078448A1	HPK1 KINASE INHIBITOR AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF Provided are an HPK1 kinase inhibitor, a preparation method therefor and the use thereof. The kinase inhibitor can adjust (for example, inhibit) HPK1 kinase activity, and thus can be used for treating various HPK1-related diseases includ...
WO/2024/081318A1	ANTI-VIRAL COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2024/077391A1	THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are o...
WO/2024/081889A1	4H-PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES FOR TREATING CANCER This disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα). These compounds are useful for treating a disease...
WO/2024/076989A1	BIFUNCTIONAL CHIMERIC MOLECULES FOR LABELING OF KINASES WITH TARGET BINDING MOIETIES AND METHODS OF USE THEREOF The present disclosure relates to chimeric small molecules, which find utility as modifiers of target substrates according to the formula A-L1-E-B or A-L1-E-L2-B, wherein A is a kinase binding moiety; B is a target binding moiety; L1 and...
WO/2024/076300A1	COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING Compounds of the general formula (I) as described and defined herein, in particular compounds of formula (II), methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of sa...
WO/2024/077006A1	FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF Described herein are radiotherapeutics that target tumor cells expressing the follicle-stimulating hormone receptor (FSHR) and their use in the treatment and/or diagnosis of cancer.
WO/2024/074501A1	PROCESS FOR THE FLUORINATION AND/OR CYCLIZATION OF AN AMINO ALKENE OR ALKYNE IN A CONTINUOUS STREAM AND FACILITY FOR PERFORMING THE PROCESS The present invention relates to a process for the fluorination and/or cyclization of an amino alkene or alkyne in a continuous-stream microreactor. The invention also relates to a facility for performing such a process.
WO/2024/075696A1	IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE The present invention addresses the problem of providing a novel compound having an SMG1 inhibitory activity and an anticancer effect, or a pharmaceutically acceptable salt thereof etc.　A compound represented by formula (1) or a pharma...
WO/2024/067819A1	PIPERIDINE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR, AND USE THEREOF A piperidine-containing polycyclic derivative modulator, a preparation method therefor, and use thereof. In particular, the present invention relates to a compound represented by general formula (II-a), a preparation method therefor, a p...
WO/2024/069646A1	IMPROVED PROCESS FOR THE PREPARATION OF RISDIPLAM AND ITS INTERMEDIATES The present invention relates to an improved process for the preparation of Risdiplam compound of Formula-I. The present invention also relates to novel intermediates of Risdiplam compound of Formula-I and process for the preparation of ...
WO/2024/067793A1	FUSED RING COMPOUNDS AND USE THEREOF Provided in the present disclosure are compounds represented by formula (I) or pharmaceutically acceptable salts, pharmaceutical compositions comprising same, and the use thereof. The compounds are particularly suitable for preparing dru...
WO/2024/073658A1	HYDANTOIN MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION The subject matter described herein is directed to myelin-promoting compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of admin...
WO/2024/067820A1	TRICYCLIC COMPOUNDS AS CDK INHIBITORS AND METHODS OF USING SAME Provided are novel tricyclic compounds as CDK inhibitors, which are useful for treating diseases or conditions mediated by CDKs, particularly cancers and other diseases caused by abnormal cell proliferation. Preparation methods, pharmace...
WO/2024/072793A1	PYRIDINE CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
WO/2024/067433A1	NOVEL PRMT5 INHIBITOR AND USE THEREOF The present invention describes a novel molecule with inhibitory activity against protein arginine methyltransferase 5 and methods for synthesis and use of the compound. Specifically, the present invention describes a compound of formula...
WO/2024/067660A1	AZA-FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE The present disclosure relates to an aza-fused ring compound, a preparation method therefor, and a use thereof in medicine. Specifically, the present disclosure relates to an aza-fused ring compound represented by general formula (I), a ...
WO/2024/073507A1	MACROCYCLIC COMPOUNDS AND USES THEREOF Described herein are macrocyclic compounds of Formulas (Al), (BI), and (CI) which can inhibit kinases such as EGFR, including mutant forms such as T790M EGFR mutants. Also described herein are pharmaceutical compositions comprising a com...
WO/2024/071398A1	ABHD6 ANTAGONIST The purpose of the present invention is to provide a drug for the prevention and/or treatment of diseases associated with ABHD6, said drug containing a compound having ABHD6 inhibitory activity as an active ingredient. A compound represe...
WO/2024/067691A1	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Disclosed are a nitrogen-containing heterocyclic compound and pharmaceutical use thereof. Specifically, disclosed are a nitrogen-containing heterocyclic compound represented by general formula (I), a preparation method therefor, a pharma...
WO/2024/072794A1	PYRIDINE CARBOXAMIDE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS The invention provides pyridine carboxamide compounds, pharmaceutical compositions, and their use in treating medical conditions.
WO/2024/067575A1	NITROGEN-CONTAINING POLYCYCLIC COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Disclosed are a nitrogen-containing polycyclic compound, and a pharmaceutical composition and use thereof. The nitrogen-containing polycyclic compound of the present invention is a nitrogen-containing polycyclic compound represented by f...
WO/2024/071219A1	SULFONAMIDE COMPOUND, AND HARMFUL-ARTHROPOD EXTERMINATION COMPOSITION CONTAINING SAME According to the present invention, a compound represented by formula (I) (wherein, Q (# denotes a bonding site with a sulfur atom, and ● denotes a bonding site with Het) represented in the formula denotes a group or the like represent...
WO/2024/067845A1	IMIDAZOPYRIDINE COMPOUND AS IRAK4 DEGRADATION AGENT AND USE THEREOF An imidazopyridine compound represented by formula (I) as an IRAK4 degradation agent, a tautomer thereof, a stereoisomer thereof, a hydrate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The...
WO/2024/073371A1	AKT1 MODULATORS Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
WO/2024/067714A1	COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY The present invention provides compounds having the structure of formula (I) and being capable of being used as a KRAS inhibitor, a pharmaceutical composition comprising the compounds, a method for preparing the compounds, and use of the...
WO/2024/061370A1	PYRIMIDINE-FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF Disclosed in the present invention is a pyrimidine-fused ring compound having an inhibitory effect on KRAS gene mutation, or a pharmaceutically acceptable salt, stereoisomer or solvate thereof. In addition, further disclosed in the prese...
WO/2024/064026A1	AKT1 MODULATORS Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising the inhibitory compounds, and methods for using the AKT1 inhibitory compounds for the treatment of disease.
WO/2024/062871A1	PHOTOELECTRIC CONVERSION DEVICE, IMAGING DEVICE, PHOTOSENSOR, AND COMPOUND The present invention addresses the problem of providing a photoelectric conversion device, an imaging device, a photosensor, and a compound that are excellent with respect to vapor deposition production applicability, electromagnetic st...
WO/2024/061345A1	HPK1 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF The present application belongs to the field of medicines, and provides an HPK1 inhibitor, a preparation method therefor, and use thereof. Particularly, disclosed are a compound of formula (I'), a preparation method therefor, a pharmaceu...
WO/2024/060966A1	PAN-KRAS INHIBITOR COMPOUND The present invention relates to a pan-KRAS inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inflam...
WO/2024/061118A1	MACROCYCLIC NITROGEN-CONTAINING CROWN ETHER COMPOUND AND USE THEREOF AS PROTEIN KINASE INHIBITOR The present invention provides a macrocyclic nitrogen-containing crown ether compound represented by formula (I) and use thereof as a protein kinase inhibitor.
WO/2024/061554A1	PHARMACEUTICAL COMPOUND A PARP7 inhibitor compound comprises formula (I), X1 is selected from C, and N. R1, R2, and R3, are each independently H or an organic group. R9 is H or an organic group, or is absent when X1 is N. L is (II). Each R4 is independently sel...
WO/2024/063143A1	FUSED RING COMPOUND HAVING GLP-1 RECEPTOR AGONIST EFFECT The present invention relates to a compound represented by formula (I) or (II) or a pharmaceutically acceptable salt thereof.　Formula (I): [wherein: A1 is C(R1), etc.; R1 is a hydrogen atom, etc.; R8 is a hydrogen atom, etc.; B1 is CH,...
WO/2024/061365A1	PYRIMIDINE FUSED RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Provided are a compound represented by formula (I), or a tautomer, a cis-trans isomer, a mesomer, a racemate, an enantiomer, a diastereomer, or an atropisomer thereof, or a mixture form thereof, or a pharmaceutically acceptable salt, a s...

Matches 1 - 50 out of 9,425	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >